Purpose To determine the test-retest repeatability of Apparent Diffusion Coefficient (ADC) measurements across institutions and MRI vendors, plus investigate the effect of post-processing methodology on measurement precision. Methods Thirty malignant lung lesions >2 cm in size (23 patients) were scanned on two occasions, using echo-planarDiffusion-Weighted (DW)-MRI to derive whole-tumour ADC (b = 100, 500 and 800smm -2 ). Scanning was performed at 4 institutions (3 MRI vendors). Whole-tumour volumes-ofinterest were copied from first visit onto second visit images and from one post-processing platform to an open-source platform, to assess ADC repeatability and cross-platform reproducibility.
). Scanning was performed at 4 institutions (3 MRI vendors). Whole-tumour volumes-ofinterest were copied from first visit onto second visit images and from one post-processing platform to an open-source platform, to assess ADC repeatability and cross-platform reproducibility.
Results Whole-tumour ADC values ranged from 0.66-1.94x10 -3 mm 2 s -1 (mean = 1.14). Within-patient coefficientof-variation (wCV) was 7.1% (95% CI 5.7-9.6%), limits-ofagreement (LoA) -18.0 to 21.9%. Lesions >3 cm had improved repeatability: wCV 3.9% (95% CI 2.9-5.9%); and LoA -10.2 to 11.4%. Variability for lesions <3 cm was 2.46 times higher. ADC reproducibility across different postprocessing platforms was excellent: Pearson's R 2 = 0.99; CoV 2.8% (95% CI 2.3-3.4%); and LoA -7.4 to 8.0%. Conclusion A free-breathing DW-MRI protocol for imaging malignant lung tumours achieved satisfactory within-patient repeatability and was robust to changes in post-processing software, justifying its use in multi-centre trials. For response evaluation in individual patients, a change in ADC >21.9% will reflect treatment-related change. Key Points • In lung cancer, free-breathing DWI-MRI produces acceptable images with evaluable ADC measurement.
• ADC repeatability coefficient-of-variation is 7.1% for lung tumours >2 cm.
• ADC repeatability coefficient-of-variation is 3.9% for lung tumours >3 cm.
• ADC measurement precision is unaffected by the postprocessing software used.
• In multicentre trials, 22% increase in ADC indicates positive treatment response. 
Introduction
Diffusion-weighted MRI derived Apparent Diffusion Coefficient (ADC) is emerging as a potentially valuable imaging biomarker for quantifying treatment response in a number of tumour types, including in lung cancers. It is being applied as an end point in an increasing number of clinical trials both outside [1] [2] [3] and within the lung (Table 1 , [4, 5] ). In order to utilize change in ADC as a response biomarker, uncertainty in its quantitation must be lower than the change following treatment, which in lung tumours ranges between 16-90% (Table 1) . Therefore, in order to detect meaningful change with treatment, it is desirable that the uncertainty of the ADC measurement is <16%. This measurement uncertainty must include calculation of marker precision and bias estimation. The latter is carried out in test objects [6] [7] [8] , while the former (defined as 'the closeness of agreement between measured quantity values obtained by replicate') is obtained through test-retest repeatability measurements under specified conditions. There are no reports of ADC measurement repeatability in lung cancers in a multi-centre setting, although inter and intra-observer coefficients of variation estimated from repeated measurements on the same data sets (reproducibility) have been estimated at 3.7-11.4% (depending on lesion size and location in the chest) [9, 10] . Methods of deriving ADC suffer from inconsistent methodology across different centres, both in data acquisition and analysis; a wide variety of lesion segmentation methodologies and software packages have been presented for ADC quantitation (Table 1 [ [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . However, even when acquisition and analysis methods are standardised, uncertainty resulting from different scanner platforms and different post-processing algorithms between institutions, which is inherent in multicentre trials, is unknown. The EORTC/CRUK imaging biomarker validation roadmap stresses the huge importance of multicentre multivendor repeatability/reproducibility studies to ensure that imaging biomarkers can translate beyond single-centre use [21] . The purpose of this study, therefore, was to determine the repeatability of ADC measurements acquired on a test-re-test basis using a common and generalizable free breathing DW-MRI protocol, across four university hospitals and three different MRI vendor platforms. It was performed under EORTC Innovative Medicines Initiative (IMI) QuIC-ConCePT project (Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy), for which the variation in ADC measurement precision was investigated as a function of lesion size, post-processing methodology and ADC summary statistic employed. The ultimate aim was to validate the use of ADC for treatment response assessment in lung cancer in a multi-centre setting (www.imi. europa.eu).
Materials and methods

Patients
This prospective, multicentre study was performed following local Ethics Review Board approval in Italy, the Netherlands and the UK. Across four university hospitals, patients with at least one lung tumour > 2 cm in size identified on CT and without contra-indication to MRI were invited to participate. Written informed consent was obtained for the 27 patients enrolled (15 men, 12 women, age range 41 -86 years). Between May 2014 and September 2015, 25 of the 27 patients were scanned on two occasions >1 hour and <1 week apart (median interval 4.29 hours). In two patients, the repeatability scans were inconsistent with the imaging protocol for the study and their data was excluded from the analysis ( Table 2) . For these patients, the DW-imaging had been performed with insufficient signal averages (NSA < 4), providing lower signal-to-noise ratio than was obtained for the remaining patients. The remaining 23 patients underwent test-retest repeatability imaging according to the study protocol. Of these 23 patients, 15 patients had primary lung cancer (14 NSCLC and one small cell lung cancer (SCLC)), eight had metastatic lung lesions (three from colorectal carcinoma; one from renal cell cancer; and one uterine leiomyosarcoma), and three had an undocumented primary site. Six of the 23 patients were treatment naïve (five of whom had lung cancer and one metastatic renal cell cancer). The other 17 had either received treatment >1 week prior to enrolment (chemotherapy or radiotherapy to lungs in 11 patients), or treatment status was not documented by the scanning site (six patients). For the 11 in whom prior treatment had been documented, six received chemotherapy alone, three received a combination of chemotherapy and radiotherapy and two had received radiotherapy alone. The mean interval between end of treatment and baseline scan was 63 weeks, so that no on-going post-treatment effects were present. Analysis was possible for 30 lung lesions >2 cm in size. 
Quality assurance
Quality assurance was carried out prior to scanning and then every 3 months, using a previously described temperature controlled sucrose phantom, to confirm ADC stability on the 1.5 T MR scanners at the four sites [22] .
Image data Acquisition
All imaging experiments were performed during free breathing, using phased-array body coils (two anterior and two posterior elements) on the following platforms: GE Optima 1.5 T (site A); Philips Achieva 1.5 T (sites B and G); Siemens Avanto 1.5 T (site E). DW-MR imaging comprised twice refocused spin-echo sequences with single-shot echo planar readout, using a short-tau inversion recovery (STIR) fat suppression technique, over a large field of view. The 5 mm transverse slices with no slice gap were obtained through the whole lung, using 30-60 slice scanning volumes per series of DW images. Each series of DW images was either performed four times, or once with NSA = 4 (GE, and Philips). Images were acquired at three b-values (100, 500 and 800 s/mm 2 ). DW sequence parameters included b values greater than 100 s/ mm 2 , in order to reduce the effects of perfusion on the ADC estimate ( Table 2) .
Anatomical images of the whole chest were also obtained, using axial T1-weighted (T1-W) turbo spin-echo sequence and a three-dimensional (3-D) T2-W turbo spin echo sequence with variable flip angle.
Image data analysis
Bright regions on the high-b value images that are iso-or hypo-intense to spinal cord on the ADC maps are features that have been shown to differentiate tumour from pleural fluid or pulmonary collapse and were used to delineate tumours [23] Co-registration of the free breath b800 images with the end expiratory SPACE images is an interesting observation (Fig. 1) . With reference to the high b-value images and ADC maps (so as to differentiate tumour from adjacent atelectasis), tumour size (maximum lesion dimension) was evaluated on the anatomical T1W imaging using an electronic calliper (performed in OsiriX, Pixmeo, Geneva, Switzerland).
Segmentation was performed on every slice on which tumor was present, to encompass the whole tumour cross section, by an experienced radiologist (AW) using both a region growing technique (where a user defined seed is grown and checked by the operator for registration, to include all nearest neighbour pixels that lie within the mean +/-a specified number of standard deviations of the original seed mean value -ADEPT, Institute of Cancer Research, UK) and a freehand drawing technique (OsiriX). Freehand segmentation in Osirix was performed with reference to the region growing boundaries defined in ADEPT, in order to define anatomically co-registered tumour regions on the two software packages (Fig. 2) .
Whole-tumour segmentation was performed on the computed (or 'virtual') high b (=800 smm -2 ) value images rather than the acquired b = 800smm -2 images as the former provide higher SNR, in combination with good image quality and background suppression, while at the same time ensuring exact anatomical registration with the ADC images [24] . Segmentation was performed for images obtained at the first patient visit (DWI-1), for all lesions that were: (a) >2 cm in size and; (b) present on at least three consecutive slices. These regions were copied slice by slice onto anatomically coregistered tumour regions on images obtained at the second patient visit (DWI-2), so as to generate anatomically matched test-retest ADC measurements.
ADC and computed DW-MR images were generated by applying a mono-exponential decay model to signal decay with increasing b-value (Levenberg-Marquardt algorithm) in both software packages [24] . Measurements generated in OsiriX were used to calculate multi-centre, cross vendor, within-patient ADC test-retest repeatability.
For those lesions in which image analysis was possible on the two different post-processing platforms (25 of 30 lesions), the reproducibility of the ADC measurement using two different software packages was evaluated.
Statistical analysis
Statistical analysis was performed in Graph-pad Prism Version 6 (GraphPad Software Inc., CA, USA). Data used Fig. 2 Comparative ROIs generated using axial images in two different post-processing packages. (a) ROI generated using axial images in ADEPT (b800 image). (b) ROI generated using axial images in ADEPT (ADC image). (c) ROI generated using axial images in Osirix (b800 image). (d) ROI generated using axial images in Osirix (ADC image) for comparison was tested for normality (d'Angostino Pearson) and log-transformed if non-normal. Normally distributed data were compared using Student's t-test.
Test-retest repeatability and measurement precision for whole tumour median ADC (ADC med ) was assessed with Bland-Altman plots, as well as by calculating Limits of Agreement (LoA), within subject Coefficient of Variation (wCV), and intra-class correlation (ICC). These parameters were calculated for ADC values measured for all lesions and separately for lesions 2-3 cm and lesions > 3 cm. Differences in test-retest ADC med measurement variability between scanning institutions (sites A, B, E and G) were assessed using one-way ANOVA. Variability for this purpose was defined by the difference in ADC value per lesion on test-retest scanning [(ADC-1) -(ADC-2)]. Differences in ADC measurement variability based on lesion size (<3 cm versus >3 cm) were assessed using the F-test [25] . For the ADC values generated on the two post-processing platforms, differences between the absolute ADC values and test-retest ADC value variability were assessed for significance using paired Student's t-test. For this analysis, difference in ADC variability using each post-processing platform was calculated by considering: [(ADC-1) -(ADC-2)] ADEPT ; compared with [(ADC-1) -(ADC-2)] OsiriX . Pearson's correlation coefficient was also calculated for ADC estimates derived using the two post processing platforms and agreement of ADC values between the platforms was assessed using Bland-Altman analysis and the concordance correlation coefficient (CCC) (8) .
The influence of ADC summary statistic on repeatability used was assessed by calculating wCV, LoA, ICC and measurement variability [(ADC-1) -(ADC-2)] for whole tumour mean ADC values (ADC mean ), as had previously been performed for ADC med . ADC mean testretest variability was compared with corresponding ADC med variability using the paired Student's t-test. In addition, Pearson's R 2 , concordance correlation coefficient and coefficient of variation (CoV) between paired ADC mean and ADC med values were calculated. The absolute ADC values (ADC med and ADC mean ) were also compared for difference using the Student's t-test with (Holm-Bonferroni corrected) level of significance set as p = 0.0125.
Results
ADC measurements of the test object from all scanners at all time-points fell within the expected range, indicating that quality assurance specifications for the study were met [22] .
Evaluable lesions ranged in size from 21 to 94 mm (Table 3) The highest value of ADC was recorded for patient 4, in whom artefact from a subcutaneous metallic foreign body distal to but at the same level as the treatment naive right upper lobe NSCLC is likely to have influenced diffusion weighted signal decay.
Averaged ADC med values and the repeatability of whole lesion analysis from the two imaging time-points are summarized in Table 3 . Within patient ADC med coefficient of variation (wCV) for all lesions was: 7.1% (95% CI 5.7 -9.6%); limits of agreement (LoA) were -18.0 to 21.9%; and ICC was 0.94 (95% CI 0.88 to 0.97). The equivalent repeatability Considering the effect of lesion size, ADC med repeatability for lesions > 3 cm (n = 16) is summarised by: wCV of 3.9% (95% CI 2.9 -5.9%); LoA -10.2 to 11.4%; and ICC 0.98 (95% CI 0.95 to 0.99). In comparison, ADC med measurement variability for lesions <3 cm (n = 14) was c. 2.5 times higher, with: wCVof 9.6% (95% CI 7.0 -15.2%); LoA -23.3 to 30.5%; and ICC 0.92 (95% CI 0.77 to 0.97). This difference in ADC measurement variability for lesions >3 cm compared with lesions < 3 cm reached statistical significance [F(15,13) = 0.13, p = 0.0002]. Bland Altman plots in Figure 3 (a-c) summarise these data. Comparing lesions >3 cm with lesions <3 cm, no significant difference was observed between these groups in terms of either the interval between scans (MannWhitney p = 0.24) or prior treatment status (Fischer exact test p = 0.17). From the one-way ANOVA, the scanning institution had no significant effect on test-retest ADC med measurement variability [F(3,26) = 0.87, p = 0.47)], a result that is confirmed by the overlapping 95% confidence intervals for wCV (Table 3 , Fig. 3 (d) ). Similarly, there was no significant difference in absolute ADC med values between primary and metastatic lesions (p = 0.58), nor between treatment naïve and previously treated patients (p =0.74).
ADC reproducibility using two different post-processing software packages was possible for DW-MRI performed at sites A, B and E. For five lesions scanned at site G, due to storing and transfer of the image data in a 'JPEG lossless' format, in which grey-scale bit-depth of the DICOM files is compressed, quantitative analysis was not possible on ADEPT (IDL). For the remaining 25 lesions, agreement (measured on a per-lesion basis) between ADC med values generated on two different post-processing platforms was excellent, Table 4 ). This is demonstrated graphically in the correlation, Bland Altman and box-plots in Fig. 4 . In addition, for the two different postprocessing platforms, no significant differences were seen in terms of either the absolute ADC med values generated (p = 0.13) or for test-retest ADC med variability (p = 0.73).
Discussion
This study demonstrates a wCV of < 10% for ADC (both median and mean values) in malignant lung lesions across multiple institutions, using a whole lung DW-MRI protocol during free breathing and different post-processing software packages. It is the first study to confirm multi-centre withinpatient test-retest repeatability in malignant lung lesions and indicates that within a clinical trial, a measured ADC change of >22% is an acceptable threshold for indicating response, as it would be above the 95% limits of agreement for test-retest scanning (LoA = -18.0 to 21.9%). This change is a little greater than the change recorded following treatment in some single centre reports in the literature (Table 1) . Nevertheless, the similarity of the absolute ADC values between data in these reports and our cohort endorses our ADC repeatability measurement and justifies its use in future multicentre clinical trials [6] . However, due to the wide range of individual ADC test-retest variability, generalisability of our findings to assess response of individual patients in the clinical setting would require justification. Our data nonetheless demonstrates acceptable cohort wCV, for the purpose of measuring treatment-related change in a clinical trial. Furthermore, ADC is a very promising biomarker that will allow quantitative interrogation of tumour microstructure and cell membrane integrity (http://qibawiki.rsna.org/index.php), potentially reflecting treatment-induced changes early during therapy, where size based measurements are non-informative because they do not reflect changes in tumour biology [26] .
The choice of ADC summary statistic significantly altered absolute ADC values: ADC med was significant different from ADC mean , despite strong correlation between the two values. This is likely due to the bimodal ADC distribution within mixed necrotic/solid tumours. This difference highlights the importance of consistent methodology within and between trials before absolute ADC measurements can be compared, so as to mitigate against risks [27] . Repeatability was equivalent for both metrics, indicating that choice of either metric is acceptable. The effect of lesion size on ADC repeatability for lung tumours is in line with prior reports on reproducibility [9] . Significantly better repeatability was seen for lesions >3 cm than smaller lesions. This reflects the greater effect of respiratory motion on smaller lesions. When respiratory excursion in the z-axis is greater than half of tumour size, volume averaging between normal lung and tumour occurs for all locations within tumour. It is interesting to note that for lesions <3 cm in size, half of this dimension was similar to the mean diaphragm excursion expected during quiet respiration, reported in prior studies to lie between 1.4 to 1.7 cm [9, 28] . This effect of lesion size is also likely to have accounted for differences in wCV observed between institutions in our study -Site E had greater mean lesion size than site A and tendency to a lower wCV, although this latter difference did not reach statistical significance. Use of motion compensation protocols when assessing small lesions may well be warranted in the future in a single centre setting. Any measures employed should take into account the dependence of respiratory motion upon tumour location in the chest [29] .
Perfusion related ADC bias was minimised by using b = 100 s/mm 2 as the lowest b-value [30, 31] with the upper bvalues dictated by previously observed ADC values in lung tumours ( [32, 33] , Table 1 ). The b = 500 s/mm 2 acquisition ensured that ADC values from predominantly mucinous/ necrotic tumours (high ADC) were accurately represented, as in these tumours signal at b = 800 s/mm 2 has a significant noise contribution. The satisfactory ADC measurement repeatability in lung tumours has enabled roll-out into a The free breathing protocol used in this study is easily implemented in multicentre trials and both generalizable across centres and suitable for the lung cancer patient group, in whom breath-hold capacity is limited. Ease of implementation was a strong factor in devising the protocol, and it could be further refined if proposed for single centre use. For example, motion compensation measures could be applied at the expense of scan duration in the single centre setting [9] , where image quality may be improved by reducing the effect of respiratory motion. One limitation of our data is that lesions < 2 cm were not included in the analysis. Future evaluation of smaller lesions would be best achieved after applying a successful respiratory compensation protocol.
The effect of gradient non-linearity on ADC accuracy and reproducibility has been highlighted as an area of concern for clinical trials and poor inter-scanner reproducibility has been cited as reducing the diagnostic value of ADC [34] . In light of this, each patient included in this study had examinations performed on the same scanner with identical acquisition parameters at each visit. However, even when using the same scanner, changing tumour position within the B0 field and relative to the DWI scanning volume can distort tumour ADC estimates, due to non-linearity of both the spatial encoding and diffusion encoding gradients [34] . Inconsistent patient position is likely to have a negative impact on repeatability, a factor that was minimised in our study by consistent patient and scanning volume positioning by dedicated research technologists.
It is interesting to note that no significant difference was observed between ADC values for treatment naïve patients compared with patients that had received treatment. Lesion segmentation in our study included necrotic areas of tumour for some patients, potentially leading to bias in the ADC measured, while for patient 4 (treatment naïve), a metallic artefact at the same slice position as the tumour caused encoding and diffusion gradient distortion. However, the small difference in ADC between the two imaging time-points for this patient (1.34%) indicates that any artefact induced alteration of ADC did not have an adverse effect on repeatability.
Our data demonstrate the robustness of mono-exponential log linear ADC fitting. Prior reports have shown that postprocessing of quantitative MRI parameters can have a profound impact measurement uncertainty, especially with dynamic contrast enhancement [35] [36] [37] . In our analysis of ADC, the fact that the two software packages did not utilize perfectly matched regions of interest at each location within tumours (because we were unable to export regions of interest from one package to the next), demonstrated the robustness of ADC measurement in the chest. The region growing segmentation methodology is a technique previously shown to produce acceptable intra-and inter-observer reproducibility [9] and our analysis illustrates that cognitive registration of regions matched between software packages on the b = 800 smm -2 images suffices. To be clinically meaningful, the measurement needs to be repeatable across multiple observers, software platforms and imaging platforms [2, 38] . This study adds to existing data by confirming the validity of postprocessing on a widely available, open-source DICOM browser such as Osirix. The data from this study provides 
Conclusion
We have demonstrated satisfactory test-retest repeatability and reproducibility of ADC measurements in lung tumours, using an easily implemented free breathing DW-MRI protocol across multiple institutions. These results justify the more widespread interrogation of ADC as a potential biomarker in phase II and III clinical trials, where its role in predicting outcomes following therapy now requires evaluation [39] . If proposed for more widespread use, ADC also provides a robust measurement that is not unduly influenced by different post processing software packages, showing very close agreement and satisfactory reproducibility between our in house analysis software and open-source DICOM browser-based Osirix. Further interrogation of the methodology, including with motion compensation and high-resolution single lesion coverage would be essential before applying ADC quantitation to individual patients in the clinical setting.
